How Retatrutide Works: The Triple-Agonist Mechanism

The mechanism in plain terms

How does retatrutide work? The short version: your body uses three hormones — GIP, GLP-1, and glucagon — to regulate hunger, blood sugar, and calorie burning. Retatrutide is engineered to activate the receptors for all three at once, using a single molecule. No approved drug does this. Prior drugs in this class activate one (GLP-1 only) or two (GLP-1 + GIP) receptors.

Activating the GLP-1 receptor reduces appetite and slows how quickly your stomach empties. Activating the GIP receptor improves how cells respond to insulin after eating. Activating the glucagon receptor turns up your body's calorie-burning rate and tells the liver to break down stored fat. The combination of all three is why retatrutide has produced larger weight reductions in trials than any prior drug in its class. This is the core of how retatrutide works — and the rest of this page walks through the molecular detail.

Structure: a 39-amino-acid GIP-based peptide

Retatrutide is a 39-amino-acid synthetic peptide (amino acids — the building blocks that proteins are made from; 39 of them in a specific sequence constitute this compound) built on a GIP-based backbone. Its molecular formula is C₂₂₁H₃₄₂N₄₆O₆₈ and its molecular weight is approximately 4,731 daltons (Da — a unit of molecular mass equal to the mass of one hydrogen atom).

The molecule carries a C20 fatty-diacid modification — a 20-carbon fatty-acid chain attached to the peptide — that binds it to albumin (the most abundant protein in blood plasma). This albumin binding is what extends the half-life to approximately 6 days, making once-weekly dosing feasible ^[4]. Without this modification, a peptide of this size would clear from the bloodstream within hours.

Receptor binding: what cryo-EM showed

Cryo-EM (cryo-electron microscopy — an imaging technique that photographs molecular structures at near-atomic resolution by rapidly freezing them and bombarding them with electrons) studies resolved retatrutide's simultaneous binding to all three receptors at resolutions of 2.68 Å (GLP-1R), 3.26 Å (GIPR), and 2.84 Å (GCGR) ^[3]. Angstroms — Å — are units of distance at the atomic scale (one Å = 10⁻¹⁰ meters); at these resolutions, individual amino acid positions in the binding interface are visible.

The structural data revealed something specific about retatrutide's relative potencies. At the GIPR, it is approximately 8.9 times more potent than the body's own GIP hormone. At the GCGR (glucagon receptor), it is 0.3 times as potent as native glucagon. At the GLP-1R, 0.4 times as potent as native GLP-1 ^[3]. The lower relative potency at GCGR and GLP-1R is by design — full glucagon receptor activation would raise blood sugar, which is undesirable in an anti-obesity compound. The calibrated glucagon arm adds energy expenditure without the hyperglycemic (blood-sugar-raising) effect of full glucagon agonism.

The extracellular loop 1 (ECL1 — a structural loop of the receptor that the drug makes contact with) adopts a rigid alpha-helical conformation in both GLP-1R and GCGR when retatrutide binds, but a flexible loop in GIPR — a structural difference that may explain the higher GIPR relative potency ^[3].

The three receptor effects and why they combine

GLP-1 receptor arm. GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. Its receptor (GLP-1R) is expressed in the pancreas, brain, and gut. GLP-1R activation: suppresses appetite via hypothalamic signaling (the hypothalamus is the brain region that regulates hunger and satiety); triggers glucose-dependent insulin secretion (insulin release that occurs only when blood glucose is elevated, not in the fasted state); and slows gastric emptying — the rate at which food moves from the stomach into the small intestine. Slowing gastric emptying is both a satiety mechanism and the source of the GI side effects (nausea, vomiting) that are the most common adverse effects in trials ^[1].

GIP receptor arm. GIP (glucose-dependent insulinotropic polypeptide) is released from the upper small intestine after eating. GIPR activation enhances insulin secretion in a glucose-dependent manner, similar to GLP-1R, but also has effects on adipose (fat) tissue — including promoting lipid (fat) storage when food is plentiful and potentially facilitating lipid release during caloric restriction. Retatrutide's 8.9× super-agonist potency at GIPR relative to native GIP amplifies this arm substantially ^[3].

Glucagon receptor arm. Glucagon is a pancreatic hormone that, in its full physiological role, raises blood glucose by stimulating the liver to release stored glucose. GCGR activation by retatrutide at calibrated (sub-full-agonist) potency adds two important effects absent in GLP-1 or GLP-1/GIP agonists: increased resting energy expenditure (calorie burning at rest) via cAMP/PKA signaling in multiple tissues, and increased hepatic lipid oxidation (breakdown of fat in the liver) ^[3][6]. This third arm is the likely contributor to retatrutide's larger weight-loss figures versus dual agonists, and to its notable liver-fat reduction ^[5][6].

Why this is not "GLP-3"

The term "GLP-3" circulates in popular media and community discussions to describe retatrutide. It is a misnomer: there is no GLP-3 receptor. GLP-1 and GLP-2 exist — GLP-2 is a separate gut hormone with different functions — but GLP-3 does not. Retatrutide is accurately described as a GIP/GLP-1/glucagon triple agonist or triagonist. The "GLP-3" label is a marketing-style simplification that does not correspond to any pharmacological target. Cryo-EM structural studies have confirmed retatrutide's binding to GLP-1R, GIPR, and GCGR specifically ^[3].

Mechanism and the kidney data

The kidney-protective signal emerging from Phase 2 data — UACR reductions of 28–37% and eGFR improvements ^[11] — is thought to reflect a combination of mechanisms: direct effects of GLP-1R and GIPR signaling on renal tubular cells, reductions in systemic inflammation and blood pressure driven by weight loss and metabolic improvement, and reduced kidney filtration demand as metabolic function normalizes. The mechanistic basis for renal benefit in incretin-class agents has been partially characterized in preclinical and clinical studies for the class as a whole ^[8], and is now being specifically evaluated for retatrutide in the TRANSCEND-CKD Phase 3 trial ^[12].

The 2026 Cardiology in Review comprehensive review frames this mechanistic landscape as the basis for retatrutide's potential role in addressing cardiovascular-kidney-metabolic syndrome ^[13] — a cluster of interconnected conditions (obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease) where metabolic dysfunction drives damage across multiple organ systems.

For the full trial outcomes data, see Retatrutide results.